D-Mannose
D-Mannose is a simple sugar (a hexose monosaccharide) found naturally in cranberries, peaches, apples, and some other fruits. It is sold in the UK as a food supplement, most commonly for urinary-tract-health support. There are no UK-authorised health claims for D-mannose. The biological rationale is well-defined: D-mannose binds the FimH adhesin on uropathogenic Escherichia coli, preventing the bacteria from sticking to the urothelial lining. The evidence base is mixed: smaller, mostly single-centre trials reported reduced recurrent-UTI rates, but the large UK primary-care MERIT randomised trial (2024) found no benefit over placebo. D-mannose has been studied for prevention in women with recurrent UTIs, not for treating acute UTIs — acute infection needs an NHS antibiotic pathway.
Camden Medicals editorial · Last reviewed 2 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Other
- Typical daily dose
- Recurrent-UTI prevention trials: 1–2 g/day. UK supplement labels: 500 mg–2 g/day. Acute-event regimens described in research: 2 g three times daily for short courses (NOT a substitute for antibiotic treatment).
- Top use evidence
- Moderate
On this page
What it is
D-mannose is the C-2 epimer of glucose — a six-carbon simple sugar with the chemical formula C₆H₁₂O₆. It occurs naturally in cranberries (the original "cranberry juice for UTI" rationale), peaches, apples, blueberries, and oranges, and at trace levels in human plasma where it forms part of glycoprotein synthesis.
Pharmacokinetically, ingested D-mannose is absorbed through the small intestine, partially metabolised, and a meaningful fraction is excreted unchanged in urine — where it accumulates at concentrations high enough to occupy bacterial FimH adhesion receptors. Unlike glucose, D-mannose has only a small effect on blood glucose at typical food-supplement doses; it is metabolised differently and largely cleared via the kidneys.
Commercial supplements are typically sold as crystalline D-mannose powder (palatable, can be dissolved in water or unsweetened juice) or in capsules (typically 500 mg per capsule, 1–6 capsules/day per label directions). The supplement-grade material is high-purity crystalline; quality differentiation between products is mostly purity, particle size, and the absence of inappropriate fillers, rather than extract ratios or standardisation as for botanicals.
At a glance
- A simple sugar that binds the FimH adhesin on E. coli, blocking the bacterium from sticking to the bladder lining and allowing it to be flushed out in urine.
- No UK-authorised health claim. Marketing must stay descriptive, not effect-claiming.
- The evidence in recurrent-UTI prevention in women is mixed — smaller earlier trials reported reduced recurrence, but the large 2024 UK primary-care MERIT randomised trial found no benefit of daily D-mannose over placebo.
- Not a treatment for acute UTI — fever, pain, blood in urine, or pyelonephritis symptoms need NHS care, not a supplement.
- Typical doses are 500–2,000 mg/day for prevention. Higher acute doses (2 g three times daily) are described in some research but should not replace antibiotics.
What people use it for
Women with recurrent uncomplicated UTIs (≥3 episodes/year or ≥2 in 6 months)
D-mannose has been studied for recurrent-UTI prevention at 2 g daily. Evidence is mixed — some smaller, mostly single-centre studies reported reduced recurrence (and one found D-mannose comparable to nitrofurantoin prophylaxis), but the large 2024 UK primary-care MERIT randomised trial found no reduction in medically attended UTI versus placebo. Camden frames this as descriptive evidence, not a health claim. [4,5]
Popular, not provenMixedAdults seeking a non-antibiotic option after antibiotic UTI courses
D-mannose has been used as a follow-on after antibiotic UTI treatment to reduce recurrence; the published evidence is supportive but heterogeneous. Discuss with your GP if you have had multiple UTI courses — there are now NICE prescribed-prophylaxis pathways too. [2]
Some evidenceModerateAnyone with red-flag UTI symptoms (fever, flank pain, blood, vomiting, pregnancy, suspected pyelonephritis)
See a clinician urgently — these need antibiotic care or hospital assessment, not a supplement. D-mannose is not pyelonephritis treatment. [1]
Popular, not provenInsufficientPeople with diabetes or impaired glucose tolerance
D-mannose is a sugar but is largely renally cleared and has limited effect on blood glucose at supplement doses. People with diabetes should still flag use to their care team and monitor glucose if starting D-mannose.
Some evidenceLimited
How it works
Most uncomplicated urinary tract infections in women are caused by uropathogenic E. coli (UPEC). UPEC adhere to bladder urothelial cells via type-1 pili tipped with the FimH adhesin, which has high affinity for mannose residues on the human uroplakin glycoprotein. Free D-mannose in urine competes with uroplakin for FimH binding — bacteria coat themselves with D-mannose instead of attaching to the bladder wall, and are flushed out on micturition. The mechanism is physical / receptor-blocking rather than antibacterial; D-mannose does not kill bacteria.
Common myths
Myth"D-mannose is a UTI treatment."
RealityIt is not for acute UTIs. The evidence base is for recurrent-UTI prevention in women — reducing the rate of new episodes over time. An acute UTI with fever, pain, or blood in urine needs NHS antibiotic care, not a supplement. [1]
Myth"D-mannose is just cranberry in capsule form."
RealityCranberry juice contains some D-mannose plus proanthocyanidins (PACs); the PACs are also active against E. coli adhesion via a different mechanism. D-mannose is the isolated sugar at much higher concentrations than cranberry juice delivers. They are related actives, not the same product. Some commercial blends combine the two.
Myth"D-mannose will cause diabetes / spike blood sugar."
RealityD-mannose is a sugar but is metabolised differently from glucose and is largely renally cleared. At food-supplement doses it has a small effect on blood glucose. People with diabetes should still flag use to their care team.
Myth"You can take D-mannose for any infection."
RealityThe mechanism (FimH receptor blockade) is specific to E. coli and a small number of related uropathogens. D-mannose is not active against most other bacteria, viruses, fungi, or against UTIs caused by non-E. coli organisms (Klebsiella, Proteus, Staphylococcus saprophyticus). About 80–90 % of uncomplicated UTIs in women are E. coli — but not all.
Common online questions
Synthesised from the questions UK shoppers most often ask online about D-Mannose. Each answer is editorial and links to its evidence in the Sources list below.
Can I take D-mannose if I have a UTI right now?
D-mannose is not a treatment for acute UTI. If you have UTI symptoms — burning with urination, frequency, urgency, cloudy or blood-stained urine — contact your GP, NHS 111, or a community pharmacist (UTI is now a Pharmacy First condition for women aged 16-64). Acute UTIs are treated with antibiotics; the evidence-supported role of D-mannose is to reduce recurrence after the acute episode is treated. [1]
How much should I take for prevention?
Trials in recurrent-UTI prevention have used 2 g once daily (the MERIT trial dose), or 1 g twice daily, typically for at least 3 to 6 months. Lower doses (500 mg–1 g/day) are common on UK food-supplement labels. There is no UK consensus dose; higher doses do not have stronger evidence, and the largest trial (MERIT) found no benefit at 2 g/day over placebo. [4]
Can I take D-mannose with cranberry / probiotics / antibiotics?
D-mannose has no documented antibiotic interaction and can be taken alongside an antibiotic course. Cranberry + D-mannose combinations are common and not contraindicated. Probiotics (S. boulardii in particular) are also commonly co-taken; no documented interaction. As always, talk to your pharmacist if you take prescribed medication.
Is D-mannose safe in pregnancy?
Limited published data. Pregnant women with UTI symptoms need prompt clinical care — pyelonephritis in pregnancy is serious. Talk to your midwife or GP before using D-mannose in pregnancy.
Why is the dose on the label so much smaller than the trial doses?
Many UK food-supplement labels recommend 500 mg–1 g/day; the trial doses for active prevention have been 1–2 g/day. If your clinician has suggested D-mannose for recurrent UTI prevention, check the dose against the published evidence rather than the cheapest label. The single-active D-mannose product Camden is evaluating allows up to 9 capsules/day (4.5 g), giving the consumer headroom to match trial-grade dosing.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Recurrent urinary tract infection prevention in women
MixedEvidencemixedThe 2024 MERIT trial (Hayward G et al., JAMA Internal Medicine) — a UK double-blind RCT across 99 primary-care centres in 598 women with recurrent UTIs — found that D-mannose 2 g/day did NOT reduce the proportion of women experiencing a medically attended UTI versus placebo over 6 months (51.0% vs 55.7%; risk difference −5%, 95% CI −13% to 3%), and the authors concluded D-mannose should not be recommended for prophylaxis in this group. Earlier, smaller, mostly single-centre trials (e.g. Kranjčec 2014) had reported reduced recurrence. NICE does not list D-mannose as first-line prophylaxis in CKS guidance. [4,5]
Acute UTI treatment
InsufficientEvidenceinsufficientD-mannose is not an antibiotic and is not a treatment for acute symptomatic UTI. NHS / NICE pathway is short-course antibiotic therapy (typically nitrofurantoin or trimethoprim per local antibiotic stewardship guidance). Suspected pyelonephritis, complicated UTI, or UTI in pregnancy needs urgent clinical assessment. [2]
Catheter-associated UTI prevention
LimitedEvidencelimitedSmall studies suggest a possible role; insufficient evidence for a routine recommendation. Catheter-associated UTI is a clinical-care decision, not a self-treatment one.
Inherited carbohydrate-deficient glycoprotein syndrome (CDG-Ib / MPI-CDG)
StrongEvidencestrongD-mannose is the established treatment for the rare inherited condition phosphomannose-isomerase deficiency (MPI-CDG); the international consensus guideline for MPI-CDG describes it as one of the few treatable congenital disorders of glycosylation, with a proven effect of oral mannose. This is a paediatric metabolic-medicine indication, not a food-supplement use, and is included here for completeness: the molecule has a well-characterised therapeutic role outside UTI in this niche specialty setting. [6,7,8]
Safety
D-mannose is generally well tolerated at typical food-supplement doses. The most common side effect is mild GI upset (loose stools, bloating) at higher doses or during the first few days. People with diabetes should monitor glucose if starting; pregnant women and people with kidney disease should talk to a clinician first.
Talk to your pharmacist or GP first if you:
- You are pregnant or breastfeeding — limited data.
- You have diabetes or impaired glucose tolerance — D-mannose is a sugar; effect on blood glucose is small at typical doses but worth monitoring.
- You have kidney disease — D-mannose is largely cleared renally; talk to your prescriber.
- You have UTI red flags — fever, flank pain, blood in urine, vomiting, pregnancy, or symptoms not improving — see your GP or NHS 111 / Pharmacy First. D-mannose is not acute-UTI treatment.
- Recurrent UTIs persist on D-mannose — discuss prescribed prophylaxis options with your GP (NICE CKS pathway).
Common side effects: Mild GI: bloating, loose stools, or wind, particularly at higher doses (≥3 g) or initial dosing. Settles with continued use or dose reduction.
Pregnancy and breastfeeding
Limited published data. UTI in pregnancy needs prompt clinical care; talk to your midwife or GP before starting D-mannose.
Limited data; talk to your pharmacist or GP.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Known hypersensitivity to D-mannose.
- Active acute UTI requiring antibiotic care — see GP / Pharmacy First; D-mannose is not a substitute for antibiotic therapy.
Drug interactions
- No documented clinically significant interaction with antibiotic UTI treatment — D-mannose can be taken alongside an antibiotic course.
- No documented interaction with anticoagulants or routine prescribed medication. As with any supplement, flag use to your prescriber.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI symptoms: bloating, loose stools, flatulence, particularly at higher single doses.
Rare side effects
- Allergic reactions — rare hypersensitivity reports.
- Renal effects — case reports at exceptionally high chronic intake; not a concern at food-supplement doses.
How to take it
- Typical supplemental range
- Recurrent-UTI prevention trials: 1–2 g/day. UK supplement labels: 500 mg–2 g/day. Acute-event regimens described in research: 2 g three times daily for short courses (NOT a substitute for antibiotic treatment).
- Timing
- Most prevention regimens dose once or twice daily, typically before meals or before bed. Some trials post-coital dose for women with intercourse-related recurrence.
How to spot quality
Look for
- Crystalline D-mannose explicitly named (not "mannose blend" or "mannose complex" without amount).
- Per-capsule or per-scoop dose stated in mg/g — readable without maths.
- GMP-certified manufacture; ideally supplement-grade purity (≥99 %).
- Minimal excipients — D-mannose itself is the active; capsule shell + flow agent is enough. Long ingredient lists in a "D-mannose" product are usually multi-active blends, which is fine, but should be priced and dosed differently.
- No added sugars, artificial sweeteners, or flavourings in the powder format.
Red flags
- Unstated purity / no dose declaration.
- Marketing implies acute UTI treatment (medicinal-borderline; ASA/MHRA risk).
- Marketing implies "natural antibiotic" — it is not antibacterial, the mechanism is adhesion blockade.
- Combined with herbal "blends" at unknown doses without per-active mg.
Where Camden lands · meets the bar
Camden Medicals is evaluating a single-active D-mannose product (500 mg, 180 capsules) for Phase-3 launch. It is a clean single-active formulation (D-mannose + HPMC capsule shell + magnesium stearate flow agent — that''s it), GMP-manufactured in the UK, suitable for vegans and vegetarians. Per-capsule dose (500 mg) and the recommended directions (3 capsules × 1–3 times/day, up to 9 capsules / 4.5 g/day) give the consumer headroom to match research-grade prevention dosing without forcing them into a higher-priced "extra strength" SKU. Open action: confirm purity (≥99 %) on the supplier specification sheet before launch.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Cranberry (Vaccinium macrocarpon)
Limited evidenceD-mannose and cranberry are commonly stacked for recurrent UTI prevention; the strongest individual evidence is for D-mannose monotherapy.
Most uncomplicated UTIs are caused by uropathogenic Escherichia coli that attach to the bladder urothelium via FimH adhesins on type-1 pili. D-mannose is a simple sugar that binds the FimH adhesin competitively, occupying the binding site that would otherwise attach to mannose-like residues on bladder epithelial cells. Cranberry contains A-type proanthocyanidins (PACs) that interfere with P-fimbriae adhesion through a separate mechanism. Combination supplementation is rationalised by attacking both adhesin systems; the strongest individual-component evidence is for D-mannose. Neither replaces antibiotic treatment of acute infection.
Evidence: Kranjčec 2014 (World J Urol 32:79) randomised 308 women with recurrent UTI to 2 g D-mannose powder daily, 50 mg nitrofurantoin daily, or no prophylaxis for 6 months. UTI recurrence: 14.6% (D-mannose), 20.4% (nitrofurantoin), 60.8% (no prophylaxis); D-mannose was non-inferior to nitrofurantoin and significantly better than no prophylaxis (p<0.0001). Cranberry trials (multiple) are heterogeneous and have produced mixed results; the most-recent Cochrane update found a modest reduction in recurrent UTI in women. Direct head-to-head or combination trials are sparse. [5]
Doses studied: Kranjčec D-mannose dose: 2 g powder dissolved in 200 ml water once daily for prophylaxis. Cranberry: typical 36 mg PAC standardised extract daily. Acute UTI: see GP — supplementation does not replace antibiotic treatment.